Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatment of hereditary angioedema, at the upcoming virtual Ladenburg Thalmann Healthcare Conference. The presentation will take place on Tuesday, July 13 th , 2021 at 12:30pm ET.
A webcast of the presentation will be available at the following link: https://wsw.com/webcast/ladenburg7/catb/2378558 , and will also be available in the investors section of the Company’s website, www.catabasis.com , and will be archived for 30 days following the presentation.
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope with life-changing therapies to patients and families affected by rare and niche diseases. Our lead program, QLS-215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210707005084/en/
Catabasis:
Investor relations:
Andrea Matthews
investors@catabasis.com
Media:
Elizabeth Higgins
media@catabasis.com